Theravance Biopharma (TBPH) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/8/2026
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- U.S. economy adds 172,000 jobs in May, topping expectations
- Citi warns global stock markets are the frothiest since 2008
- JPMorgan upgrades Tesla, sets new price target on robotaxi and Optimus potential
- Fed risks fueling a stock bubble by overlooking AI-driven inflation: BCA
- Earthquake of magnitude 7.8 strikes off southern Philippines, 15 feared killed
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- Marvell Technology and Flex to join S&P 500; others to join S&P MidCap 400 and S&P SmallCap 600
- SpaceX signs $920 million monthly cloud deal with Google
- Target recalls Up & Up baby wipes due to bacterial contamination
Theravance Biopharma, Inc. Reports Second Quarter 2015 Financial Results and Provides Business Update
August 10, 2015 4:15 PM EDTDUBLIN, IRELAND -- (Marketwired) -- 08/10/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported financial results for the second quarter ending June 30, 2015. Revenue for the second quarter of 2015 was $7.1 million. Net loss for the second quarter of 2015 was $47.6 million, or $1.42 per share. Cash, cash equivalents, and marketable securities, excluding restricted cash, totaled $228.8 million as of June 30, 2015.
Rick E Winningham, Chairman and Chief Executive Officer, commented: "In the first half of 2015, we have focused on executing our strategies to advance TD-4208 to a registrational Phase 3 program, creating an acute... More
Theravance Biopharma Receives FDA Fast Track Designation for TD-8954 for Use With Enteral Feeding in Critically Ill Patients
August 6, 2015 8:05 AM EDTDUBLIN, IRELAND -- (Marketwired) -- 08/06/15 -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to TD-8954 for short-term use with enteral feeding to achieve early nutritional adequacy in critically ill patients at high nutritional risk. TD-8954 is a selective 5-HT4 receptor agonist being evaluated for potential use in the treatment of gastrointestinal motility disorders, including enteral feeding intolerance (EFI). Importantly, there are currently no FDA-approved therapies for EFI, leaving the approximately one million Americans who suffer from the... More
